Prevention of restenosis by systemic drug therapy: back to the future?

Circulation. 2005 Nov 1;112(18):2759-61. doi: 10.1161/CIRCULATIONAHA.105.583484.
No abstract available

Publication types

  • Comparative Study
  • Editorial
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Cilostazol
  • Controlled Clinical Trials as Topic
  • Coronary Restenosis / prevention & control*
  • Double-Blind Method
  • Drug Administration Schedule
  • Fibrinolytic Agents / therapeutic use*
  • Humans
  • Phosphodiesterase Inhibitors / therapeutic use*
  • Pioglitazone
  • Placebos
  • Stents / adverse effects*
  • Tetrazoles / administration & dosage
  • Tetrazoles / therapeutic use*
  • Thiazolidinediones / administration & dosage
  • Thiazolidinediones / therapeutic use*
  • Tunica Intima / drug effects
  • Tunica Intima / pathology

Substances

  • Fibrinolytic Agents
  • Phosphodiesterase Inhibitors
  • Placebos
  • Tetrazoles
  • Thiazolidinediones
  • Cilostazol
  • Pioglitazone